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Abstract
The properties of the human immunodeficiency virus (HIV) pose serious difficulties for the
development of an effective prophylactic vaccine. Here we describe the construction and
characterization of recombinant (r), replication-competent forms of rhesus monkey rhadi-
novirus (RRV), a gamma-2 herpesvirus, containing a near-full-length (nfl) genome of the
simian immunodeficiency virus (SIV). A 306-nucleotide deletion in the pol gene rendered
this nfl genome replication-incompetent as a consequence of deletion of the active site of
the essential reverse transcriptase enzyme. Three variations were constructed to drive
expression of the SIV proteins: one with SIV’s own promoter region, one with a cytomega-
lovirus (cmv) immediate-early promoter/enhancer region, and one with an RRV dual pro-
moter (p26 plus PAN). Following infection of rhesus fibroblasts in culture with these rRRV
vectors, synthesis of the early protein Nef and the late structural proteins Gag and Env
could be demonstrated. Expression levels of the SIV proteins were highest with the
rRRV-SIVcmv-nfl construct. Electron microscopic examination of rhesus fibroblasts
infected with rRRV-SIVcmv-nfl revealed numerous budding and mature SIV particles and
these infected cells released impressive levels of p27 Gag protein (>150 ng/ml) into the
cell-free supernatant. The released SIV particles were shown to be incompetent for repli-
cation. Monkeys inoculated with rRRV-SIVcmv-nfl became persistently infected, made
readily-detectable antibodies against SIV, and developed T-cell responses against all
nine SIV gene products. Thus, rRRV expressing a near-full-length SIV genome mimics
live-attenuated strains of SIV in several important respects: the infection is persistent;
>95% of the SIV proteome is naturally expressed; SIV particles are formed; and CD8+
T-cell responses are maintained indefinitely in an effector-differentiated state. Although
the magnitude of anti-SIV immune responses in monkeys infected with rRRV-SIVcmv-
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nfl falls short of what is seen with live-attenuated SIV infection, further experimentation
seems warranted.
Author summary
Given the magnitude and impact of the HIV/AIDS pandemic, development of a safe,
effective vaccine against HIV remains a top priority for biomedical research. While live-
attenuated strains of the simian immunodeficiency virus (SIV) have shown promise in
monkey studies, concern for safety has limited efforts along these lines. In an attempt to
mimic the epitope presentation, epitope coverage, and persistence of live attenuated SIV,
we have generated recombinant strains of rhesus monkey rhadinovirus (RRV; a gamma-2
herpesvirus) containing a near-full-length genome of SIV. The near-full-length genome
retains 96.7% of the coding capacity of SIV yet is incompetent for replication. Such
recombinant RRV produces abundant SIV particles in infected cells in culture. Monkeys
inoculated with one of these recombinant RRV strains became persistently infected, made
readily detectable antibodies against the SIV envelope protein, and developed cellular
immune responses to all nine SIV gene products.
Introduction
There are good reasons for believing that development of an effective preventive vaccine
against HIV-1 is going to be a very difficult task [1–3]. HIV is able to replicate continuously
without relent despite apparently strong humoral and cellular immune responses to the virus.
The HIV envelope glycoprotein is shielded with a large amount of carbohydrate and the trimer
spike as it exists of the surface of virions is difficult for antibodies to access and difficult for
antibodies to block infectivity. HIV-1 is highly variable from one individual to another and
even within a single individual evolves to evade ongoing immune responses. The virus encodes
a number of gene products that function at least in part to evade intrinsic, innate and adaptive
immune responses. And during the course of an infection, HIV-1 gradually destroys CD4+ T
lymphocytes, a key orchestrator of adaptive immune responses. The inability of infection by
one HIV-1 strain to routinely provide protection against superinfection by a different HIV-1
strain supports this perception of great difficulty in development of a protective vaccine [4].
Investigation of a variety of creative, non-standard approaches to a vaccine seem justified
given this expected difficulty.
Two particular vaccine approaches have shown the greatest protective effects in monkey
studies to date using virulent strains of simian immunodeficiency virus (SIV) for challenge of
Indian-origin rhesus monkeys. The first one consists of live-attenuated strains of SIV, such as
those deleted of the nef gene, which have far and away provided the greatest degree of protec-
tion against challenge [5–8]. However, even live attenuated SIV has not provided very good
protection against challenge with SIV strains not closely matched in sequence to that of the
vaccine strain [9–11]. This last point seems consistent with the inability of infection by one
HIV-1 strain to routinely provide protection against superinfection as described in the previ-
ous paragraph. The second approach consists of live recombinant forms of a fibroblast-
adapted strain of the beta-herpesvirus rhesus cytomegalovirus (CMV). Approximately 50% of
macaques vaccinated with these CMV-based vectors manifested complete control of viral rep-
lication shortly after SIVmac239 infection [12–14]. The remaining monkeys not protected by
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this CMV-based vaccine exhibited persisting SIV levels in plasma indistinguishable from those
in control, unvaccinated monkeys. Independent recombinant CMV vectors expressing Gag, or
Pol, or Env, or a Rev-Tat-Nef fusion protein (RTN) were combined, but Env-specific antibod-
ies were not elicited.
There are a number of potential advantages to use of a recombinant herpesvirus as a vaccine
vector. Herpesviruses possess large genomes and can accommodate a large amount of inserted
genetic information. Importantly, herpesviruses persist for the lifetime of the infected host and
immune responses to their encoded proteins persist in an up, on, active fashion for life. Being
a DNA virus, any inserted genetic information can be expected to remain relatively stable for
prolonged periods. Furthermore, there are eight distinct human herpesviruses from which to
choose, each with distinct target cells for replication, sites of persistence, and composition of
genes. A live-attenuated strain of the human alpha herpesvirus varicella zoster virus is part of
childhood immunization programs in many countries [15].
Here we describe the construction and properties of a recombinant gamma-herpesvirus
(the rhesus monkey rhadinovirus, RRV) containing a near-full-length genome of SIV capable
of expressing 96.7% of its protein products.
Results
Expression of SIV-nfl in rRRV-infected rhesus fibroblasts
The complete SIVmac239 proviral genome including both LTRs is 10,279 base pairs [16]. For
the construction of near-full-length (nfl) recombinants using a different promoter/enhancer
region, we eliminated nucleotides 1–521 from the left LTR in the numbering system of Regier
and Desrosiers (Fig 1) [16]. We also eliminated nucleotides 9,864–10,279 from the right LTR
(Fig 1). The remaining sequences retain the RNA start site in the left LTR and the overlap
region with nef in the right LTR (Fig 1). A V5 tag was added to the end of nef, followed by the
BGH poly A addition site (Fig 1). In order to definitively obviate replication competence, a
306-nucleotide in-frame deletion was introduced into pol to remove the active site of the
reverse transcriptase enzyme (Fig 1). These changes retain 96.7% of the coding capacity of the
SIV genome. In one recombinant (r) construct (rRRV-SIVnfl-cmv), a CMV promoter/
enhancer region was placed just upstream of the SIV sequences. In a second construct, the SIV
promoter/enhancer region was used by restoring the 1–521 nucleotides of the left LTR
(rRRV-SIVnfl-ltr). In a third construct, a promoter construct consisting of the promoter for
RRV ORF26 (p26) and the promoter for the RRV Poly Adenylated Nuclear RNA (PAN) was
inserted just upstream of the SIV sequences (rRRV-SIVnfl-dual). ORF26 encodes a RRV cap-
sid protein and is made late during lytic RRV replication. Conversely, PAN encodes one of the
most abundant non-coding RNA transcripts of RRV and is made at the onset of lytic replica-
tion [17–20]. These constructions were inserted between the left terminal repeats and the first
open reading frame (R1) of the RRV genome using procedures previously described [21–24].
To evaluate the expression of SIV proteins, rhesus fibroblasts (RF) permissive for lytic RRV
replication were infected with rRRVs expressing SIV-nfl under the control of either the CMV
promoter, the SIVmac239 LTR region, or a promoter construct denoted RRV dual promoter,
consisting of both p26 and PAN promoters. Cell lysates were prepared and analyzed by immu-
noblotting for the presence of the particular SIV gene products. All three rRRV vectors pro-
duced the early protein Nef and the late structural proteins Gag and Env (Fig 2). The Nef
protein was the first detected with all three vectors, suggesting appropriate time-ordered syn-
thesis. Expression levels of the SIV proteins were highest in RF cells infected with the
rRRV-SIVcmv-nfl construct. Additionally, the production of the SIV late antigens was first
seen at day three post infection in the rRRV-SIVcmv-nfl-infected RF cells. The progression of
A recombinant herpesvirus with a near-full-length SIV genome
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cytophatic effect was similar with all three viruses, with rRRV-SIVdual-nfl being very slightly
slower than the other two, which is why this one goes out to day 6 rather than just day 5 in Fig
2. The observed intracellular expression levels of the SIV proteins were consistent with levels
of SIVmac239 Gag p27 detected in RF cell culture supernatants post rRRV infection. RF cells
infected with construct rRRV-SIVcmv-nfl released over 150 ng/ml of Gag p27 into the cell-
free supernatant (Fig 3A). These impressive levels of p27 are similar to what is observed follow-
ing replication of SIV in permissive cells [25, 26].
In order to confirm the production and integrity of rRRV-derived SIVnfl virions, transmis-
sion electron microscopy (TEM) analysis of rRRV-SIVcmv-nfl-infected RF cells was per-
formed. The TEM images revealed not only RRV particles but also numerous SIV particles of
appropriate size and morphology. Free SIV virions released from the cell and virions budding
from the surface of the plasma membrane were visualized (Fig 3C & 3D). Of note, some of the
extracellular released SIV particles exhibited the cylindrical or rod-shaped nucleoids of mature
Fig 1. Position of the SIVcmv-nfl expression cassette in recombinant RRV. A near full-length genome (nfl) sequence of SIVmac239 with a 520 bp deletion
(red X) in the 5’ Long Terminal Repeat (LTR) region, a deletion in the pol region spanning 306 bp, corresponding to the active site of the reverse transcriptase,
and a 414 bp deletion in the 3’ LTR region, was generated via Gibson cloning. Numbering system corresponds to that of Regier and Desrosiers [16].
Subsequently, utilizing overlaps containing PmeI restriction sites, the cytomegalovirus immediate-early enhancer and promoter (pCMV), the SIV-nfl sequence
containing a C-terminal V5-tagged nef open reading frame (ORF), and the bovine growth hormone (BGH) polyA signal were inserted between the left
terminal repeats (TR) and the first ORF R1 of RRV via Gibson cloning. Full length recombinant RRV was obtained from subsequent transfection of
overlapping cosmid clones [21].
https://doi.org/10.1371/journal.ppat.1007143.g001
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lentiviral virions. As expected, replication assays performed in CEMx174 cells confirmed that
the rRRV-derived SIVnfl particles were replication-incompetent (Fig 3B).
Infection of rhesus monkeys with rRRV-SIVcmv-nfl
Since the rRRV-SIVcmv-nfl construct resulted in high levels of SIV protein expression in
vitro, we set out to evaluate its ability to infect, persist, and elicit anti-SIV immune responses
in vivo. Six RRV seronegative rhesus macaques were inoculated intravenously with 109
genome copies of rRRV-SIVcmv-nfl (Table 1). Enzyme-linked immunosorbet assays (ELI-
SAs) were performed to monitor the development of anti-RRV and anti-SIV Env antibodies
following the inoculation. Anti-RRV antibodies emerged in all animals by week 6 post
rRRV-SIVcmv-nfl inoculation and steadily increased in the ensuing weeks (Fig 4A). Anti-
Env antibodies were characterized based on their ability to bind gp140 and gp120. Vaccine-
induced gp140-binding antibodies were first detected at week 6 post vaccination and
sharply increased afterward (Fig 4B). Except for monkey r11099, all animals maintained
high, stable levels of gp140-specific antibodies for the 20 weeks of measurement post
rRRV-SIVcmv-nfl inoculation (Fig 4B). Vaccine-induced gp120-binding antibodies were
also first detected at week 6 post vaccination, although only two macaques (r11005 and
r10094) exhibited a similar surge in antibody levels as was observed for gp140-binding anti-
bodies (Fig 4C). Vaccine-elicited gp120-binding antibodies were still increasing in r10094
and r11015 at week 20 post vaccination, the last follow up (Fig 4C). By comparison, these
responses remained at low levels in the remaining rRRV-SIVcmv-nfl vaccinated monkeys.
Serial dilutions of week 20 sera were also used to assess vaccine-induced gp140- and
gp120-binding antibodies. As references, these analyses included sera from two macaques
that had been infected with SIVmac239Δnef for 18 weeks and two monkeys that had
Fig 2. Kinetics of recombinant RRV-mediated SIV-nfl expression. Early passage rhesus fibroblast (RF) cells were grown in 6-well culture plates and the cells
in each well were infected with the indicated strains of recombinant rRRV-SIV-nfl. Cells were cultured for the indicated number of days post infection prior to
harvest. Subsequently, cells were lysed, and the lysate was subjected to immunoblotting, measuring the expression levels of SIV239 Env, Gag, or Nef. The two
bands indicated with arrowheads in the immunoblotting of Gag correspond to p55 and p27. The major Env protein band is gp120; the Nef protein is 34 kDa.
For rRRV-SIVltr-nfl the pCMV was replaced with an intact 5’ SIVmac239 LTR. For rRRV-SIVdual-nfl the pCMV was replaced with a promoter construct
consisting of the RRV ORF26 promoter (p26) and the RRV Poly Adenylated Nuclear RNA promoter (PAN).
https://doi.org/10.1371/journal.ppat.1007143.g002
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Fig 3. Production of replication-defective SIV particles by rRRV-SIV-nfl. A) Early passage rhesus fibroblast (RF)
cells were grown in 6-well culture plates and subsequently infected with 3.5x109 genome copies of the indicated
recombinant SIV-nfl. The RF cell culture supernatants were collected at the indicated time points post infection and
subjected to an antigen capture assay to measure the levels of SIV Gag p27. Supernatant of uninfected RF cells served
as a negative control. B) Cell culture supernatant was harvested from early passage rhesus fibroblast (RF) cells infected
with the respective recombinant RRV-SIV-nfl strains. Subsequently, CEMx174 cells were infected with these
supernatants containing 20ng of p27 as measured by an antigen capture assay. An equal amount (20ng of p27) of
SIVmac239 wild-type virus produced in HEK239T-cells served as a positive control. The supernatants from the
CEMx174 cell cultures were collected at the indicated days post infection and were used in an antigen capture assays
measuring p27 levels. Supernatant of uninfected RF cells served as a negative control. C) Early passage rhesus
fibroblast (RF) cells grown in T75 culture flasks were infected with rRRV-SIVcmv-nfl and harvested at days 4–6 post
infection. Subsequently, the cells were fixed with 2.5% glutaraldehyde in sodium cacodylate buffer. Transmission
electron microscopic (TEM) images were taken at The Core Electron Microscopy Facility, University of Massachusetts.
Shown are SIV particles budding from cell membrane (filled arrowheads). The bar in the lower left corner represents
500 nm D) TEM image showing free SIV particles including mature SIV particles (filled arrowheads) containing
cylindrical, rod-shaped nucleoid as well as immature particles lacking any nucleoid structures (empty arrowheads).
The bar in the lower left corner represents 200 nm. In the inset on the upper right, a TEM image of recombinant RRV
derived from a separate image is shown.
https://doi.org/10.1371/journal.ppat.1007143.g003
Table 1. Characteristics of research animals.
Animal Sex Age (yrs)a Relevant MHC-I allele
r11005 Male 4.1
r11015 Male 4
r10094 Male 4.2
r11017 Female 3.9
r11089 Male 3.2 Mamu-A01
r11099 Male 3.1 Mamu-A01
a Age on the day of inoculation
https://doi.org/10.1371/journal.ppat.1007143.t001
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been inoculated with a rRRV encoding codon-modified SIVmac239 gp160 (rRRV-SIVc.m.-
env) for 19 weeks [24]. The SIVmac239Δnef vaccinees exhibited the highest levels of both
gp140- and gp120-binding antibodies (Fig 5A & 5B). While vaccination with rRRV-SIVc.
m.-env resulted in greater levels of gp120-binding antibodies than those achieved with
Fig 4. Humoral immune responses following infection of rhesus monkeys with rRRV-SIVcmv-nfl. Sera obtained at
the indicated time points following rRRV-SIVcmv-nfl inoculation were diluted 1:20 and tested for the presence of A)
anti-RRV responses via an ELISA utilizing ELISA plates coated with purified wild type RRV lysate. Reactive antibodies
were detected with a horseradish-peroxidase-conjugated anti-rhesus IgG antibody. B) Similarly, the sera were tested
for the presence of anti-gp140 antibodies via an ELISA using recombinant SIVmac239 gp140 to coat the ELISA plates.
Reactive antibodies were detected with a horseradish-peroxidase-conjugated anti-rhesus IgG antibody. C) The
obtained sera were tested for the presence of anti-gp120 antibodies via an ELISA using recombinant SIVmac239 gp120
to coat the ELISA plates. Reactive antibodies were detected with a horseradish-peroxidase-conjugated anti-rhesus IgG
antibody.
https://doi.org/10.1371/journal.ppat.1007143.g004
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rRRV-SIVcmv-nfl (Fig 5A), reactivity to gp140 was comparable among recipients of both
rRRV constructs (Fig 5B).
We also evaluated neutralizing activity against SIVmac316 and SIVmac239 using sera
obtained at week 20 post rRRV-SIVcmv-nfl administration (Fig 6 and Table 2). SIVmac316 is
an easy-to-neutralize derivative of SIVmac239 [27, 28]. Sera from all monkeys were capable of
neutralizing SIVmac316 with ID50 titers ranging from 1:16 to 1:794 (Fig 6; Table 2). Little or
no neutralizing activity was detected against the difficult-to-neutralize SIVmac239 clone.
Fig 5. SIV gp120/140 reactivity at week 20 post rRRV-SIVcmv-nfl inoculation. A) Sera obtained at week 20
following rRRV-SIVcmv-nfl inoculation were serially diluted and tested for the reactivity to gp120 via an ELISA using
recombinant SIVmac239 gp120 to coat the ELISA plates. Subsequently, reactive antibodies were detected with a
horseradish-peroxidase-conjugated anti-rhesus IgG antibody. Furthermore, sera of two SIVmac239Δnef-infected
animals (week 18 post infection) and sera obtained from two monkeys that had received rRRV expressing a codon-
modified version of SIVmac239 gp160 (week 19 post inoculation) were tested [24]. B) Similarly, the monkey sera were
serially diluted and tested for reactivity to gp140 by ELISA, using recombinant SIVmac239 gp140 to coat the ELISA
plates. Reactive antibodies were detected with a horseradish-peroxidase-conjugated anti-rhesus IgG antibody.
https://doi.org/10.1371/journal.ppat.1007143.g005
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Vaccine-induced SIV-specific cellular immune responses in peripheral blood mononuclear
cells (PBMC) were also evaluated. Two of the rRRV-SIVcmv-nfl-vaccinated monkeys (r11089
and r11099) expressed the major histocompatibility complex class I (MHC-I) allele Mamu-
A01, which allowed us to track vaccine-induced SIV-specific CD8+ T-cells by fluorochrome-
labeled MHC-I tetramer staining [29]. Mamu-A01 tetramers folded with peptides corre-
sponding to the immunodominant Gag CM9 (amino acids 181–189) and Tat SL8 (amino
acids 28–35) were chosen for this analysis. Vaccine-induced Gag CM9-specific CD8+ T-cells
were first detected in both animals at week 4 post vaccination, when they reached a peak of
1.3% of peripheral CD8+ T-cells in monkey r11089 (Fig 7A). In animal r11099, by comparison,
these Gag-specific CD8+ T-cell responses reached their highest frequency (0.3%) at week 12
post vaccination (Fig 7A). Low levels of vaccine-elicited Tat SL8-specific CD8+ T-cells were
Fig 6. SIVmac316 neutralization titers at week 20 post rRRV-SIVcmv-nfl inoculation in rhesus monkeys. Sera
from the rRRV-SIVcmv-nfl-inoculated monkeys taken at week 20 post inoculation were serially diluted and subjected
to neutralization assays against SIVmac316 utilizing TZM-bl cells. A pool of sera from SIVmac239-infected monkeys
served as a positive control and pooled sera from specific pathogen free (SPF) monkeys as a negative control. The
dashed line indicates 50% relative light units representing 50% neutralization activity.
https://doi.org/10.1371/journal.ppat.1007143.g006
Table 2. Serum neutralization of SIVmac316 at week 20 post rRRV-SIVcmv-nfl vaccinationa.
ID50 titers
Animal SIVmac316
r11005 152
r11015 794
r10094 469
r11017 192
r11089 296
r11099 16
SPFb <4
Positive poolc >50,000
a The ID50 titers are defined as the serum dilution that results in 50% reduction in SIV infectivity, as measured by the
TZM-bl assay.
b SPF, pooled sera of specific pathogen free monkeys.
c Positive pool, pooled sera of SIVmac239-infected monkeys.
https://doi.org/10.1371/journal.ppat.1007143.t002
A recombinant herpesvirus with a near-full-length SIV genome
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007143 June 18, 2018 9 / 21
detected in both animals at week 4 post vaccination (Fig 7B). While these responses reached a
peak of 1.8% of peripheral CD8+ T-cells in r11089 at week 12 post rRRV-SIVcmv-nfl inocula-
tion, they remained at a low frequency in r11099 until week 20 (Fig 7B). By that time, CD8+ T-
cell responses against both Gag CM9 and Tat SL8 had decayed considerably in the two Mamu-
A01+ vaccinees (Fig 7A & 7B).
We also combined MHC-I tetramer staining with multi-color flow cytometry to evaluate
the memory phenotype of vaccine-elicited SIV-specific CD8+ T-cells at week 10 post SIVcmv-
nfl inoculation. This analysis relied on the differential expression of CD28 and CCR7 by cen-
tral memory (TCM; CD28+CCR7+), transitional memory (TEM1; CD28+CCR7-), and termi-
nally differentiated effector memory (TEM2; CD28-CCR7-) CD8+ T-cells in rhesus macaques
[30]. The vast majority of Gag CM9- and Tat SL8-specific CD8+ T-cells in r11089 exhibited
either the TEM2 or TEM1 signature, consistent with the persistent nature of the rRRV-SIVcmv-
nfl vector (Fig 8A). The low frequencies of tetramer+ CD8+ T-cells in r11099 at week 10 post
vaccination made it difficult to accurately delineate the memory phenotype of vaccine-elicited
CD8+ T-cells in this animal (Fig 8B). However, based on the few tetramer+ CD8+ T-cells ana-
lyzed, TEM2 and TEM1 subsets appeared to predominate (Fig 8B). Most tetramer+ CD8+ T-
cells in r11089 also expressed high levels of the cytotoxicity-associated molecule Granzyme B
(Fig 9A). A smaller fraction of tetramer+ CD8+ T-cells in r11099 also appeared to express
Granzyme B, albeit at low levels (Fig 8B).
To further evaluate the breadth of vaccine-elicited SIV-specific T-cell responses in the
rRRV-SIVcmv-nfl-inoculated monkeys, we carried out intracellular cytokine staining (ICS)
assays in PBMC at weeks 10 and 18 post rRRV-SIVcmv-nfl inoculation. Peptide pools corre-
sponding to eight of the nine SIV proteins were used in the first assay–Pol was the only protein
absent from that analysis. Vaccine-elicited CD8+ T-cell responses against all eight SIV proteins
were detected, especially against Nef (Fig 9A). SIV-specific CD4+ T-cells were also detected at
this time point, although they focused on Gag and were present at much lower frequencies
(Fig 9B). To further characterize the breadth of vaccine-elicited T-cell responses, we repeated
the ICS assay at week 18 using separate pools of peptides corresponding to each of the nine
SIV gene products. Nef remained the most frequently targeted viral protein by vaccine-elicited
CD8+ T-cells, although abundant Pol- and Tat-specific CD8+ T-cells were also present at this
time point (Fig 9C). CD8+ T-cell reactivity against the Vif and Env pools was either negative
Fig 7. rRRV-SIVcmv-nfl vaccination elicits Gag CM9- and Tat SL8-specific CD8+ T-cell responses in Mamu-A01+
macaques. Fluorescently-labeled Mamu-A01 tetramers folded with peptides corresponding to the Gag CM9 (A) or Tat SL8 (B)
epitopes were used to monitor the ontogeny of vaccine-induced CD8+ T-cell responses in the two Mamu-A01+ rRRV-SIVcmv-
nfl-inoculated monkeys (r11089 and r11099).
https://doi.org/10.1371/journal.ppat.1007143.g007
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or at borderline levels in most animals, even though responses against these two proteins were
measured in at least one animal at week 10 post rRRV-SIVcmv-nfl inoculation (Fig 9C). The
frequency of vaccine-elicited SIV-specific CD4+ T-cells at week 18 was even lower than that
measured at week 10 (Fig 9B & 9D). In sum, despite the high animal-to-animal variability in
Fig 8. Memory phenotype of vaccine-induced CD8+ T-cell responses in Mamu-A01+ rRRV-SIVcmv-nfl vaccinees. The
frequencies of Mamu-A01/Gag CM9 and Mamu-A01/Tat SL8 tetramer+ CD8+ T-cells in PBMC at week 10 post rRRV-SIVcmv-nfl
inoculation are shown in the left panels for r11089 (A) and r11099 (B). The middle panels show the delineation of memory subsets
within the tetramer+ gate based on the differential expression of CD28 and CCR7. Three subsets were identified: central memory
(TCM; CD28+CCR7+), transitional memory (TEM1; CD28+CCR7-), and effector memory (TEM2; CD28-CCR7-). The histograms in the
right panels show the levels of granzyme B expressed by tetramer+ CD8+ T-cells (blue lines). The red lines correspond to tetramer
+ CD8+ T-cells stained with an isotype-matched control monoclonal antibody.
https://doi.org/10.1371/journal.ppat.1007143.g008
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these ICS assays, these data illustrate the capacity of rRRV-SIVcmv-nfl to elicit T-cell responses
against all nine SIV gene products.
Discussion
Herpesviruses have a number of potential advantages when being considered as vectors for
vaccine delivery. Herpesviruses have large DNA genomes and can potentially accommodate
significant amounts of inserted genetic information. That potential advantage has been borne
out in our study described here in that 9,343 base pairs of genetic information have been suc-
cessfully inserted. Being a DNA virus, inserts can be expected to be reasonably stable in the
absence of direct repeats in the insert and with the absence of severe selective disadvantage.
Furthermore, herpesviruses persist for the life of the infected individual and immune
responses to their proteins persist in an up, on, active fashion for life. This is important when
considering vaccine approaches for HIV/AIDS since immunological memory will probably
Fig 9. Intracellular cytokine staining analysis of vaccine-induced SIV-specific T-cell responses in rRRV-SIVcmv-nfl-inoculated macaques. The magnitude
and specificity of vaccine-elicited CD8+ (A) and CD4+ (B) T-cell responses were measured in PBMC by ICS using pools of peptides (15mers overlapping by 11
amino acids) spanning the appropriate SIVmac239 proteins. In the week 10 assay (A & C), Vpx and Vpr peptides were grouped in a single pool and so were the
Rev and Tat peptides. Pol peptides were omitted in the week 10 assay. In the week 18 assay (B & D), 1–3 peptide pools corresponding to individual SIVmac239
proteins were used as stimuli. The percentages of responding CD8+ T-cells or CD4+ T-cells displayed were calculated by adding the frequencies of positive
responses producing any combination of three immunological functions (IFN-γ, TNF-α, and CD107a). Lines represent medians and each symbol corresponds to
one vaccinee.
https://doi.org/10.1371/journal.ppat.1007143.g009
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never be enough to contain HIV-1; once a memory response kicks in for a previously-vacci-
nated, subsequently-infected individual, HIV-1 will employ its vast array of immune evasion
and other strategies to allow continuous viral replication. Our results indeed indicate that
rRRV-SIVnfl established persistent infection in RRV seronegative monkeys. Antibody
responses increased to high levels and persisted through the 20 weeks of analysis. Similarly, cel-
lular responses persisted to one extent or another in the 20 weeks of follow-up analyses. Also,
the responding CD8+ T cells exhibited an effector memory phenotype consistent with recur-
rent antigen production. In contrast to the unconventionally MHC-restricted CD8+ TEM
responses elicited by the 68.1 rhesus CMV vaccine developed by Hansen et al. [12–14],
rRRV-SIVnfl-vaccinated macaques developed CD8+ T-cells capable of recognizing immuno-
dominant SIV epitopes restricted by classical MHC class I molecules.
We are not aware of any live vector system that has attempted what we have described here,
i.e. insertion of a nearly complete SIV or HIV genome capable of expression of all nine viral
gene products. Ourmanov et al. have described insertion of gag-pol and env genes of SIV into a
single recombinant modified vaccinia Ankara (rMVA) vector and the ability of the proteins
expressed from this construct to assemble into SIV virion particles [31]. However, six of the
SIV genes are not present in this rMVA vector and the infection of monkeys is not persistent.
While live attenuated strains of HIV-1 are not likely to be tried in people anytime soon, find-
ing other ways to mimic them would seem to be a worthwhile goal. The characteristics of the
rRRV-SIVnfl strains described here parallel what many consider to be important features for
the relative success of live attenuated SIV in monkeys. The infection appears to be persistent,
probably lifelong;>95% of the SIV proteome is naturally expressed; virion particles are formed
in abundance; and CD8+ T cell responses are maintained indefinitely in an effector-differenti-
ated state. Can we reasonably expect rRRV-SIVnfl to perform as well as live attenuated SIV in
monkey vaccine/challenge experiments, particularly since the magnitude of anti-SIV immune
responses with rRRV-SIVcmv-nfl fell considerably short of what is seen with live-attenuated
SIV infection? It is important to remember in this regard that we have so far tested only one
strain of rRRV-SIVnfl in monkeys and that the level of transgene expression in cultured cells is
not always predictive of the magnitude of the immune response to that transgene product. For
example, a rRRV vector with a CMV promoter/enhancer region driving expression of an SIV
env gene with an expression-optimized codon usage expressed high levels of Env protein in cul-
tured cells but failed to elicit detectable anti-Env antibodies in vivo [22]. In contrast, rRRV
expressing a version of SIV env with a sub-optimal codon usage capable of being induced by
the RRV transinducer ORF57 elicited readily-detectable anti-Env antibodies in infected mon-
keys [24]. Consequently, no matter how rRRV-SIVcmv-nfl performs in monkey vaccine/chal-
lenge experiments, a variety of rRRV-SIVnfl vector designs will need to be compared for the
magnitude, persistence and nature of the immune responses to the SIV products and their abil-
ity to protect against SIV challenge. Furthermore, there may be ways of enhancing the protec-
tive effects of rRRV-SIVnfl, for example by priming or boosting regimens.
Materials and methods
Research animals and ethics statement
The details regarding animal welfare described herein are either similar or identical to those
published recently [32]. “The Indian rhesus macaques (Macaca mulatta) utilized in this study
were housed at the Wisconsin National Primate Research Center (WNPRC). All animals
were cared for in accordance with the guidelines of the Weatherall report and the principles
described in the National Research Council’s Guide for the Care and Use of Laboratory Ani-
mals under a protocol approved by the University of Wisconsin Graduate School Animal Care
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and Use Committee” (animal welfare assurance no. A3368-01; protocol no. G005022) [33].
“Furthermore, the macaques in this study were managed according to the animal husbandry
program of the WNPRC, which aims at providing consistent and excellent care to nonhuman
primates at the center. This program is employed by the Colony Management Unit and is
based on the laws, regulations, and guidelines promulgated by the United States Department
of Agriculture (e.g., the Animal Welfare Act and its regulations, and the Animal Care Policy
Manual), Institute for Laboratory Animal Research (e.g., Guide for the Care and Use of Labo-
ratory Animals, 8th edition), Public Health Service, National Research Council, Centers for
Disease Control, and the Association for Assessment and Accreditation of Laboratory Animal
Care International. The nutritional plan utilized by the WNPRC is based on recommendations
published by the National Research Council. Specifically, macaques were fed twice daily with
2050 Teklad Global 20% Protein Primate Diet and food intake was closely monitored by Ani-
mal Research Technicians. This diet was also supplemented with a variety of fruits, vegetables,
and other edible objects as part of the environmental enrichment program established by the
Behavioral Management Unit. Paired/grouped animals exhibiting stereotypical and/or incom-
patible behaviors were reported to the Behavioral Management staff and managed accordingly.
All primary enclosures (i.e., stationary cages, mobile racks, and pens) and animal rooms were
cleaned daily with water and sanitized at least once every two weeks.” Lights were on a 12:12
diurnal schedule. Vaccinations were performed under anesthesia (Ketamine administered at
5–12 mg/kg depending on the animal) and all efforts were made to minimize suffering. Eutha-
nasia was performed at the end of the study or whenever an animal experienced conditions
deemed distressful by one of the veterinarians at the WNPRC. All euthanasia were performed
in accordance with the recommendations of the Panel on Euthanasia of the American Veteri-
nary Medical Association and consisted of an IV overdose (greater than or equal to 50 mg/kg
or to effect) of sodium pentobarbital or equivalent, as approved by a clinical veterinarian, pre-
ceded by ketamine (at least 15 mg/kg body weight) given by the intramuscular (IM) route.
Additional animal information, including MHC-I, age at the beginning of study, and sex, is
shown in Table 1.
Cell culture
Early passage rhesus fibroblasts (RFs) were cultured and maintained in Dulbecco’s modified
Eagle medium (DMEM, Thermo Fisher Scientific), supplemented with 20% fetal calf serum
(Thermo Fisher Scientific), and primocin (InvivoGen). TZM-bl cells (ATCC) were cultivated
in DMEM DMEM medium (Thermo Fisher Scientific), supplemented with 10% fetal calf
serum (Thermo Fisher Scientific), and primocin (InvivoGen). CEMx174 cells (NIH AIDS
Reagent Program) were cultivated in RPMI 1640 medium (Thermo Fisher Scientific), supple-
mented with 10% fetal calf serum (Thermo Fisher Scientific), and primocin (InvivoGen).
Generation of recombinant rhesus monkey rhadinovirus
A plasmid containing proviral SIVmac239 DNA served as a template for the generation of a
near full-length genome (nfl) sequence of SIVmac239. Two polymerase chain reactions (PCR)
led to two SIVmac239 sequence fragments. The primers used were forward primer; ACTTAAG
CTTGGTACCGAGCTCGGATCCTCGCTCTGCGGAGAGGCTGGC and reverse primer;
GAGTTCCTTTGACTGTAAAACTCCTGCAGGGTGTGGTATTCC, as well as forward
primer; GGAATACCACACCCTGCAGGAGTTTTACAGTCAAAGGAACTC and reverse
primer; CCACTGTGCTGGATATCTGCAGAATTCGCGAGTTTCCTTCTTGTCAGC.
Subsequently, using the PCR-derived BamHI and EcoRI overlaps the SIV-nfl sequence was
Gibson cloned (New England BioLabs) into expression plasmid pcDNA6/V5 His A (Thermo
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Scientific), hereby generating a SIVnfl sequence containing a 520 bp deletion in the 5’ Long
Terminal Repeat (LTR) region, a deletion in the pol region spanning 306 bp, corresponding
to the active site of the reverse transcriptase, and a 414 bp deletion in the 3’ LTR region. Fur-
thermore, the stop-codon after the nef open reading frame (ORF) was deleted resulting in a
pcDNA6-derived V5-tag following nef. A subsequent PCR using the pcDNA6-SIV-nfl plasmid
as a template, the forward primer; AGGTACTAGTCCGGCGCCCCGTTTAAACTGACACC
TACTCAGACAATGCGAT and reverse primer; ACTATGTGTTACTACTAGTTGTTTAAA
CTGCTTCGCGATGTACGGGCCAGAT yielded a construct comprised of the cytomegalovi-
rus immediate-early enhancer and promoter (pCMV), the SIV-nfl sequence containing a C-ter-
minal V5-tagged nef ORF, and the bovine growth hormone (BGH) polyA signal. Subsequently,
utilizing PmeI restriction site overlaps, the SIVnfl construct was cloned into cosmid ah28dA/H
between the left terminal repeats (TR) and the first ORF R1 of RRV via Gibson assembly (New
England BioLabs). Full length Recombinant RRV was made via co-transfection of five overlap-
ping cosmids as previously described [21]. Recombinant RRV-infected RF culture supernatants
were harvested, spun down twice at 2000 rcf for 5 min to remove any cell debris, and resulting
virus titers were measured via quantitative real-time PCR using a RRV latency-associated
nuclear antigen (LANA) specific primer set. The reaction was completed using the TaqMan
Fast Virus 1-Step Master Mix (Thermo Fischer Scientific) in a Real-time PCR thermocycler
(Thermo Fisher Scientific); Forward primer; ACCGCCTGTTGCGTGTTA, reverse primer;
CAATCGCCAACGCCTCAA, reporter; FAM- CAGGCCCCATCCCC. FAM- CAGGCCC
CATCCCC. High-titered recombinant RRV stocks were aliquoted and stored frozen.
Expression of SIV-nfl in RFs
For immunoblotting experiments, 2.0×105 RFs were seeded into wells of a 6-well plate. The
next day, cells were infected with 50 μL of a stock of recombinant RRV containing 109 genome
copies/ml expressing either SIVcmv-nfl, SIVlrt-nfl, or SIVdual-nfl. Cells were kept in culture
up to six days. Every day cells of one well infected with the respective rRRV were harvested up
until the cells were exhibiting advanced cytopathic effect.
Immunoblotting
Cells were harvested, resuspended, and lysed with an NP40-based lysis buffer including a pro-
tease inhibitor (Roche). Cell lysates were spun down to remove any cell debris. Subsequently,
supernatants were transferred into new tubes and their protein levels were measured and nor-
malized using a bicinchoninic acid protein assay kit (Pierce). Each lysate was mixed with an
equal volume of 2x SDS Laemmli sample buffer (Sigma-Aldrich) containing 2-mercaptoetha-
nol. Then, samples were incubated at 97 ˚C for 10 min and separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins from the gels were
transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad) and subjected to
immunoblotting. Furthermore, the PVDF membranes were blocked with 1 x PBS containing
5% skim milk briefly and incubated with the appropriate primary antibodies directed against
specific SIV antigens overnight at 4 ˚C. Three wash steps in PBS containing tween were fol-
lowed by incubation with the appropriate HRP-conjugated secondary antibodies. After a final
washing procedure, specific signals were detected with a LAS4000 mini system (GE Healthcare
Systems) using SuperSignal West Pico chemiluminescent substrate (Pierce).
rRRV-SIV-nfl-derived p27 measurements
Two hundred and fifty thousand RF cells were seeded into 6-well culture plates and subse-
quently infected with a total of 3.5×109 genome copies of SIVcmv-nfl or SIVdual-nfl. Cell
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culture supernatants were collected daily and all samples were subjected to a commercial anti-
gen capture assay (ABL) to measure the levels of SIVmac239 Gag p27. Supernatant of unin-
fected RF cells served as a negative control.
SIV replication assay
Cell culture supernatant from rRRV-SIV-nfl-infected, early passage RFs were taken. Subse-
quently, CEMx174 cells were infected with these supernatants containing a total of 20 ng of
SIVmac239 Gag p27. Gag p27 levels were measured by a commercial antigen capture assay
(ABL). Additionally, 20ng of Gag p27 of HEK293T cell-produced wild type SIVmac239 served
as a positive control. The supernatants from the CEMx174 cell cultures were collected daily
post infection and were subsequently used in an antigen capture assays measuring Gag p27 lev-
els (ABL). Supernatant taken from cultures of uninfected RF cell served as a negative control.
Transmission electron microscopy
One million early passage RF cells were seeded into T75 culture flasks. The following day, cells
were infected with 200 μL containing 2.0×108 genome copies of rRRV-SIVcmv-nfl. cells were
then harvested at days four to six post infection. Subsequently, the cells were fixed with 2.5%
glutaraldehyde in sodium cacodylate buffer. Subsequent transmission electron microscopic
(TEM) images were taken at the Core Electron Microscopy Facility, University of Massachu-
setts, according to published procedures [34].
Vaccination with rRRV-SIVcmv-nfl
One milliliter of PBS containing 109 genome copies of rRRV-SIVcmv-nfl was administered to
six rhesus macaques intravenously.
Enzyme-linked immunosorbent assays (ELISA)
Sera from all research animals were tested for the presence of gp120-binding antibodies.
ELISA plates were coated with recombinant gp120 of SIVmac239 (Immune Technology) for 1
h at 37 ˚C and the plates were then washed with PBS Tween20 (Sigma-Aldrich). Subsequently,
the ELISA plates were blocked with PBS containing 5% of skim milk (Bio-Rad). The monkey
sera were diluted 1:20 in blocking buffer and applied to the ELISA plate. Then, ELISA plates
were incubated for 1 h at 37 ˚C and the plates washed again. Subsequently, an HRP-conjugated
goat anti-rhesus IgG H+L antibody (SouthernBiotech) was added and the ELISA plates incu-
bated for one h at 37 ˚C. Sequentially, TMB substrate (SouthernBiotech) and stop solution
(SouthernBiotech) were added. Lastly, the absorbance at 450 nm per well was read in a micro-
plate reader (PerkinElmer).
Similarly, sera from all six research animals were tested for the presence of antibodies
against SIVmac239 gp140 by coating the ELISA plates with homologous purified protein
and probing the samples with a horseradish-peroxidase-conjugated anti-rhesus IgG antibody
(SouthernBiotech).
All sera were also screened for the presence of anti-RRV antibodies by coating ELISA plates
with purified RRV lysate and subsequently probing of samples (diluted 1:20) with a horserad-
ish-peroxidase-conjugated anti-rhesus IgG antibody (SouthernBiotech).
SIVmac316 neutralization assays
Sera from all six research animals were screened for neutralization of SIVmac316 utilizing the
TZM-bl assay, as described previously [35]. The ID50 titer is defined as the reciprocal of the
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highest dilution of serum that reduced SIVmac316 infectivity by 50%. Values were calculated
using the Sigmoidal, 4PL, X is log(concentration) equation in Prism7 (GraphPad Software).
MHC-I tetramer staining and memory phenotyping of CD8+ T-cells
The tetramer staining assays performed as part of the time course analysis of vaccine-induced
SIV-specific CD8+ T-cells in Mamu-A01+ macaques (Fig 7) was done by labeling PBMC with
titrated amounts of fluorochrome-conjugated Mamu-A01/Gag CM9 (MBL International
Inc.) or Mamu-A01/Tat SL8 (Tetramer Core Facility) tetramers [29]. Up to 800,000 PBMC
were incubated with the respective tetramers at 37 ˚C for 1 hr and then stained with fluoro-
chrome-labeled monoclonal antibodies (mAbs) directed against the surface molecules CD3
(clone SP34-2) and CD8α (clone RPA-T8). After a 25-min incubation at RT, the cells were
washed and then fixed with PBS containing 2% of paraformaldehyde. Data were acquired with
a SORP BD LSR II (BD BioSciences, San Jose, CA) flow cytometer and analyzed with FlowJo
software version 9.9.3 (Tree Star, Inc. Ashland, OR). CD3+ T cells were gated within the lym-
phocyte gate defined by the forward and side-scatter properties. Tetramer positive cell fre-
quencies were determined within the CD3+CD8+ cell population.
The following description of how the memory phenotype and granzyme B content of tetra-
mer+ CD8+ T-cells were determined is either identical or similar to that used in one of our
recent publications [36]. “Up to 8.0×105 cells were incubated in the presence of the appropriate
fluorochrome-labeled tetramer at 37 ˚C for 1 h and then stained with monoclonal antibodies
(mAbs) directed against the surface molecules CD3 (clone SP34-2), CD8α (clone RPA-T8),
CD28 (clone 28.2), CCR7 (clone 150503), CD14 (clone M5E2), CD16 (clone 3G8), and CD20
(clone 2H7). Amine-reactive dye (ARD; Live/DEAD Fixable Aqua Dead Cell Stain; Life Tech-
nologies) was also added to this mAb cocktail. After a 25-min incubation at room temperature,
we treated the cells with BD FACS Lysing Solution (BD Biosciences) for 10 min and subse-
quently washed them with “Wash Buffer” (Dulbecco’s PBS with 0.1% BSA and 0.45 g/L NaN3).
Cells were permeabilized by treatment with “Perm buffer” [1X BD FACS Lysing Solution 2
(Beckton Dickinson) and 0.05% of Tween-20 (Sigma-Aldrich)] for 10 min. Cells were then
washed once and stained with a Granzyme B-specific mAb (clone GB12). After a 30-min incu-
bation in the dark at room temperature, cells were washed and stored at 4 ˚C until acquisition.
Samples were acquired using FACS DIVA version 6 on a Special Order Research Product
BD LSR II apparatus equipped with a 50-mW 405-nm violet, a 100-mW 488-nm blue, and a
30-mW 635-nm red laser.
We used FlowJo 9.6 (Treestar, Inc.) to analyze data. First, we gated on diagonally clustered
singlets by plotting forward scatter height (FSC-H) versus FSC area (FSC-A) and then side
scatter height (SSC-H) versus SSC area (SSC-A). Next, we created a time gate that included
only those events that were recorded within the 5th and 90th percentiles and then gated on
“dump channel” negative, CD3+ cells. At this stage, we delineated the lymphocyte population
based on its FSC-A and SSC-A properties and subsequently gated on CD8+ cells. After outlin-
ing tetramer+ cells, we conducted our memory phenotyping analysis within this gate. Cells
stained with fluorochrome-labeled mAbs of the same isotypes as the anti-Granzyme B, anti-
CD28, and anti-CCR7 mAbs guided the identification of the memory subsets within the tetra-
mer+ population. Based on this gating strategy, the tetramer frequencies shown in Fig 9 corre-
spond to percentages of live CD3+ CD8+ tetramer+ lymphocytes.”
Intracellular cytokine staining (ICS) assay
Pools of peptides (15mers overlapping by 11 amino acids) spanning all nine SIVmac239 gene
products were used for T-cell stimulation in the week 18 assay. Given the large size of Gag,
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Pol, and Env, the peptides covering these polyproteins were divided in 2, 3, and 2 pools,
respectively. Peptides spanning each of the remaining accessory (Vpr, Vpx, Vif, and Nef) and
regulatory (Rev and Tat) proteins were grouped in individual pools. For the week 10 assay,
Vpx and Vpr peptides were grouped in a single pool, as were the Rev and Tat peptides. Pol
peptides were not used in the week 10 assay. The final assay concentration of each 15mer was
1.0 μM. The following description on how the ICS assays were set up is nearly identical to that
used in our recent publications [32]. “PBMC obtained from the research animals were stimu-
lated with the appropriate pools of SIVmac239 peptides in RPMI 1640 medium supplemented
with GlutaMax (Life Technologies), 10% FBS (VWR), and 1% antibiotic/antimycotic (VWR)
containing co-stimulatory mAbs against CD28 and CD49d for 9 h at 37 ˚C in an incubator
with a 5.0% CO2 concentration. Moreover, a phycoerythrin-conjugated mAb specific for
CD107a was included in the assay. Brefeldin A (Biolegend, Inc.) and GolgiStop (BD Biosci-
ences) were added to all tubes 1 h into the incubation time to inhibit any protein transport.
Surface molecules of cells were stained as mentioned above and cells were fixed with a 2%
paraformaldehyde solution. In addition to the same mAbs against CD14, CD16, and CD20
and the ARD reagent described above, the surface staining master mix also included mAbs
against CD4 (clone OKT4; Biolegend, Inc.) and CD8 (clone RPA-T8; Biolegend, Inc.). Cells
were permeabilized by resuspending them in “Perm Buffer” (1× BD FACS lysing solution 2
(Beckton Dickinson) and 0.05% Tween-20 [Sigma-Aldrich]) for 10 min and subsequently
washed with Wash Buffer. Cells were then incubated with mAbs against CD3 (clone SP34-2),
IFN-γ (clone 4S.B3), TNF-α (clone Mab11), and CD69 (clone FN50) for 1 h in the dark at RT.
After this incubation was completed, the cells were washed and subsequently stored at 4 ˚C
until acquisition. The data were analyzed by gating first on live CD14–CD16–CD20–CD3+
lymphocytes and then on cells expressing either CD4 or CD8 but not both markers. Functional
analyses were conducted within these two compartments. Cells were considered positive for
IFN-γ, TNF-α, or CD107a only if they co-expressed these molecules with CD69, a marker of
recent activation. Once the appropriate gates were created, we employed the Boolean gate plat-
form to generate a full array of possible combinations, equating to 8 response patterns when
testing three functions (23 = 8). Leukocyte activation cocktail (LAC; BD Pharmingen)-stimu-
lated cells stained with fluorochrome-labeled mAbs of the same isotypes as those against IFN-
γ, TNF-α, and CD107a guided the identification of positive populations. We used two criteria
to determine if responses were positive. First, the frequency of events in each Boolean gate had
to be at least two-fold higher than their corresponding values in background-subtracted nega-
tive-control tests. Second, the Boolean gates for each response had to contain10 events. The
magnitude of responding CD4+ or CD8+ T-cells was calculated by adding the frequencies of
positive responses producing any combination of IFN-γ, TNF-α, and CD107a. All calculations,
including background subtraction and evaluation of the frequencies of responding cells, were
performed with Microsoft Excel.”
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